<DOC>
	<DOC>NCT02919475</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.</brief_summary>
	<brief_title>Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>A diagnosis of RA prior to the Screening Visit. Active disease despite ongoing therapy with up to two nonbiologic diseasemodifying antirheumatic drugs, including methotrexate at both the Screening and Baseline Visits. Screening hsCRP â‰¥1.2 x upper limit of normal (ULN). Prior/current exposure to biologic and/or kinase inhibitor therapy. Known history or presence of polyneuropathy of any cause and no presence of clinically active compression neuropathy, radiculopathy or plexopathy at the Screening Visit. Positive test results for human immunodeficiency (HIV) virus, hepatitis B virus or hepatitis C (HCV) virus at the Screening Visit. Positive drug of abuse and alcohol test results. History of a clinicallysignificant infection that required oral antimicrobial or antiviral therapy within 8 weeks prior to Day 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>JTE-051</keyword>
	<keyword>Active Rheumatoid Arthritis</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>